Therapeutic Apheresis in Japan
A. Kawamura
DOI: https://doi.org/10.1046/j.1526-0968.2003.00102.x
2003-12-01
Therapeutic Apheresis and Dialysis
Abstract:In Japan, the medical cost of therapeutic apheresis (plasma exchange, double filtration, cryofiltration, adsorption, leukocytapheresis, hemofiltration etc.) is widely covered by the insurance of our government. As a result, many patients with many different conditions such as multiple myeloma, macroglobulinemia, fulminant hepatitis, chemical poisoning, myasthenia gravis, malignant rheumatoid arthritis, systemic lupus erythematosus, thrombotic microangiopathy, blood type-incompatible pregnancy, post operative hepatic failure, Guillan–Barré syndrome, pemphigis, bullous pemphigoid, hemolytic uremic syndrome, familial hyperlipidemia, arteriosclerosis obliterans, ABOincompatible renal transplantation, acute hepatitis, severe acute pancreatitis, ulcerative colitis, Crohn’s disease and so on are treated by therapeutic apheresis. Therefore, various types of apheresis equipment have been developed to treat these conditions. In particular, the membranes for the filters are improving over time. These developments are supported by the existence of many maintenance hemodialysis patients in Japan. Certainly, the medical costs of these patients are completely guaranteed by our government (see Table 1). Recently, however, some individuals in our government have expressed an interest in reassessing these guaranteed treatments. Some figures related to the medical costs of the therapeutic apheresis in Japan are shown in Table 1. In this issue of Therapeutic Apheresis and Dialysis , Yokoyama et al. present valuable work relating to the use of immunomodulation in renal diseases. Ishida et al. show important strategies for apheresis therapy in ABO-incompatible renal transplantations and Lennertz et al review cases of acute humoral rejection post kidney transplantation mediated by plasmapheres. Dr Sakata, myself and colleagues would also like to make known the recent studies of leukocytapheresis for inflammatory bowel disease in Japan. In developed countries, centrifugal leukocytapheresis is common. In Japan, however, this treatment is rare for the reason that a centrifugal machine is expensive and requires a large space (as many Western people say, we Japanese live like rabbits in a hutch). Moreover, historically we have recognized that a centrifugal machine is primarily used for blood collection at the Red Cross. Thus, we have been for the most part developing the filter leukocytapheresis (Imugard, Terumo; Cellsorba, Asahi), non-woven polyester fiber filter (A. Kawamura, Asahi), cryofiltration (Y. Nosé, A. Kawamura) and monocytegranulocytapheresis (K. Sawada, Nihon Koutaiken). Treatment by these methods is easy and safe but the cost of these devices is relatively expensive. The appearance of the immunomodulation effect as the leukocytes are exposed to the filter fibers and/or adsorbents is now also being considered. I will further clarify in this issue of the Journal more about this immunomodulation effect using the fiber filter. Therefore, we usually utilize the filter and/or adsorption system in Japan. Needless to say, they both show good functionality for removing the leukocytes. Certainly, leukocytes are removed physically by centrifugal method, but the immunomodulation effect is not exhibited with this method.